Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$3.49 -0.9%	$4.04	$2.60 ▼ $7.77	$198.10M	1.77	189,081 shs	217,901 shs
PHVS Pharvaris	$16.99 -0.3%	$15.27	$11.51 ▼ $25.50	$888.41M	-2.85	73,890 shs	15,489 shs
RCUS Arcus Biosciences	$8.28 -2.9%	$8.40	$6.50 ▼ $18.98	$876.73M	0.88	829,134 shs	1.19 million shs
ZYME Zymeworks	$11.31 -0.1%	$11.86	$8.21 ▼ $17.70	$786.92M	1.24	606,870 shs	658,545 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	+6.60%	-25.27%	+19.32%	-17.95%	-24.95%
PHVS Pharvaris	-0.35%	-4.54%	+44.04%	-6.83%	-18.27%
RCUS Arcus Biosciences	+7.71%	-0.93%	+21.97%	-32.13%	-43.93%
ZYME Zymeworks	-0.09%	-12.11%	+14.23%	-20.73%	+24.94%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSGN Design Therapeutics	0.689 of 5 stars	2.0	0.0	0.7	2.5	0.6
PHVS Pharvaris	2.1643 of 5 stars	3.5	3.0	3.2	0.8	0.0
RCUS Arcus Biosciences	2.9367 of 5 stars	4.5	1.0	1.8	4.2	0.0
ZYME Zymeworks	2.696 of 5 stars	3.4	0.0	3.9	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSGN Design Therapeutics	2.00	Hold	$4.00	14.61% Upside
PHVS Pharvaris	3.00	Buy	$41.67	145.24% Upside
RCUS Arcus Biosciences	2.91	Moderate Buy	$25.67	209.98% Upside
ZYME Zymeworks	2.88	Moderate Buy	$21.00	85.68% Upside

Current Analyst Ratings Breakdown

Latest DSGN, PHVS, RCUS, and ZYME Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
4/29/2025	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$28.00
4/23/2025	RCUS Arcus Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $14.00
3/11/2025	ZYME Zymeworks	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$30.00
3/10/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$12.00 ➝ $13.00
3/7/2025	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $19.00
2/26/2025	RCUS Arcus Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$18.00 ➝ $24.00
2/19/2025	RCUS Arcus Biosciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$22.00 ➝ $17.00

(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$4.96 per share	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	$7.95 per share	N/A
RCUS Arcus Biosciences	$141M	6.22	N/A	N/A	$6.17 per share	1.34
ZYME Zymeworks	$76.30M	10.31	N/A	N/A	$6.63 per share	1.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSGN Design Therapeutics	-$66.86M	-$0.88	N/A	N/A	N/A	N/A	-18.01%	-17.38%	5/14/2025 (Estimated)
PHVS Pharvaris	-$109.18M	-$2.68	N/A	N/A	N/A	N/A	-38.52%	-36.69%	5/14/2025 (Estimated)
RCUS Arcus Biosciences	-$307M	-$4.19	N/A	N/A	N/A	-102.66%	-45.59%	-22.38%	N/A
ZYME Zymeworks	-$118.67M	-$1.61	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	N/A

Latest DSGN, PHVS, RCUS, and ZYME Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	DSGN Design Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A
5/14/2025	Q1 2025	PHVS Pharvaris	-$0.80	N/A	N/A	N/A	N/A	N/A
5/8/2025	N/A	ZYME Zymeworks	-$0.45	-$0.30	+$0.15	N/A	$20.65 million	$27.11 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million
4/7/2025	Q4 2024	PHVS Pharvaris	-$0.74	-$0.68	+$0.06	-$0.68	N/A	N/A
3/10/2025	Q4 2024	DSGN Design Therapeutics	-$0.28	-$0.24	+$0.04	-$0.24	N/A	N/A
2/25/2025	Q4 2024	RCUS Arcus Biosciences	-$1.17	-$1.03	+$0.14	-$1.03	$29.38 million	$36.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSGN Design Therapeutics	N/A	34.61	34.61
PHVS Pharvaris	N/A	19.08	19.08
RCUS Arcus Biosciences	0.08	5.24	5.24
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSGN Design Therapeutics	56.64%
PHVS Pharvaris	N/A
RCUS Arcus Biosciences	92.89%
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
DSGN Design Therapeutics	31.20%
PHVS Pharvaris	11.84%
RCUS Arcus Biosciences	12.30%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSGN Design Therapeutics	40	56.76 million	38.96 million	Optionable
PHVS Pharvaris	30	52.29 million	46.10 million	Not Optionable
RCUS Arcus Biosciences	500	105.89 million	80.26 million	Optionable
ZYME Zymeworks	460	69.58 million	67.56 million	Optionable

DSGN, PHVS, RCUS, and ZYME Headlines

Recent News About These Companies

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

May 9 at 12:09 AM | seekingalpha.com

Zymeworks Inc. 2025 Q1 - Results - Earnings Call Presentation

May 8 at 10:58 PM | seekingalpha.com

Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates

May 8 at 6:56 PM | zacks.com

Blackstone Inc. Has $8.34 Million Stock Position in Zymeworks Inc. (NYSE:ZYME)

May 8 at 6:09 AM | marketbeat.com

Raymond James Financial Inc. Takes $888,000 Position in Zymeworks Inc. (NYSE:ZYME)

May 8 at 3:27 AM | marketbeat.com

Jazz Pharmaceuticals Stock Price, Quotes and Forecasts

May 7 at 5:37 PM | benzinga.com

Zymeworks Inc. (NYSE:ZYME) Shares Sold by BVF Inc. IL

May 6 at 7:30 AM | marketbeat.com

Zymeworks (ZYME) Projected to Post Earnings on Thursday

May 6 at 1:17 AM | americanbankingnews.com

Zymeworks Inc. (NYSE:ZYME) Receives $21.00 Consensus PT from Brokerages

May 5, 2025 | americanbankingnews.com

Acuta Capital Partners LLC Acquires Shares of 67,240 Zymeworks Inc. (NYSE:ZYME)

May 4, 2025 | marketbeat.com

Invesco Ltd. Reduces Position in Zymeworks Inc. (NYSE:ZYME)

May 4, 2025 | marketbeat.com

Zymeworks Inc. (NYSE:ZYME) Given Consensus Recommendation of "Moderate Buy" by Analysts

May 4, 2025 | marketbeat.com

Q2 Earnings Forecast for Zymeworks Issued By Leerink Partnrs

May 3, 2025 | marketbeat.com

Susquehanna Fundamental Investments LLC Purchases New Shares in Zymeworks Inc. (NYSE:ZYME)

May 3, 2025 | marketbeat.com

Zymeworks (ZYME) Expected to Announce Earnings on Thursday

May 3, 2025 | marketbeat.com

Leerink Partnrs Estimates Zymeworks' Q2 Earnings (NYSE:ZYME)

May 2, 2025 | americanbankingnews.com

Barclays PLC Has $3.23 Million Holdings in Zymeworks Inc. (NYSE:ZYME)

April 30, 2025 | marketbeat.com

Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline

April 28, 2025 | seekingalpha.com

Zymeworks: Poised For Growth With Platform Validation

April 28, 2025 | seekingalpha.com

JPMorgan Chase & Co. Grows Stake in Zymeworks Inc. (NYSE:ZYME)

April 28, 2025 | marketbeat.com

Zymeworks Inc.: Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

April 26, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, PHVS, RCUS, and ZYME Company Descriptions

Design Therapeutics NASDAQ:DSGN

$3.49 -0.03 (-0.85%)

As of 03:50 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Pharvaris NASDAQ:PHVS

$16.99 -0.05 (-0.29%)

As of 04:00 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Arcus Biosciences NYSE:RCUS

$8.28 -0.25 (-2.93%)

As of 03:59 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Zymeworks NYSE:ZYME

$11.31 -0.01 (-0.09%)

As of 04:00 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time